Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Hydralazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.81 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | NPC1 | O15118 | 3/20 | 0.81 |
| ▸ | RAB9A | P51151 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | TP53 | P04637 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | GOT1 | P17174 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | MPO | P05164 | 2/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | PKM | P14618 | 1/20 | 0.81 |
| ▸ | THPO | P40225 | 1/20 | 0.81 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.81 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydralazine SCHEMBL7810 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL3995896 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL2780318 | 0.88 | ALDH1A1 (0.89) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL36271 | 0.88 | GOT1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL27864907 | 0.88 | GOT1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL1173534 | 0.88 | GOT1 (1.00) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL2779460 | 0.87 | NPC1 (0.81) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Dihydralazine SCHEMBL13724517 | 0.86 | ALDH1A1 (0.93) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL1650561 | 0.86 | ALDH1A1 (0.93) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| Hydralazine SCHEMBL6787333 | 0.84 | ALDH1A1 (0.76) | ALDH1A1LMNANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0608322-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-07-22 | — | — | EP | claimed |
| US-5773023-A | BLEND OF AQUEOUS CARRIER, ACTIVE MATERIAL AND POLYACRYLAMIDE | RICHARDSON-VICKS INC. (US) | 1998-06-30 | — | — | US | claimed |
| EP-0608320-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-01-28 | — | — | EP | claimed |
| EP-0652774-B1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | PROCTER & GAMBLE (US) | 1997-05-07 | — | — | EP | claimed |
| US-5614178-A | TRANSDERMAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| CN-107913286-A | A kind of compound reserpine pharmaceutical composition and preparation method thereof | 常州制药厂有限公司 | 2018-04-17 | — | — | CN | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |